Pemazyre (Pemigatinib)

Pemigatinib is a cancer medicine for a type of bile duct cancer and some rare blood cancers that have a certain gene change. It's taken as a pill by mouth. It works by blocking a signal that tells these cancer cells to grow.

Brand names:Pemazyre
Medication

What people taking Pemazyre (Pemigatinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Pemazyre (Pemigatinib) for Bile Duct Cancer?

NameHow it went

About Pemazyre (Pemigatinib)

What It's For

Pemigatinib, sold as Pemazyre, is a targeted cancer pill for adults whose cancer is driven by a specific change in an FGFR gene. FGFR stands for fibroblast growth factor receptor, a family of proteins that relay growth signals into cells. Its main use is cholangiocarcinoma (bile duct cancer) that cannot be removed with surgery or has spread, and that has already been treated with at least one other therapy, usually chemotherapy. The tumor must carry an FGFR2 fusion or similar rearrangement, in which part of the FGFR2 gene has broken off and joined another gene. Only some bile duct cancers have this change, so it is identified by testing a tumor sample with an FDA-approved test. The FDA granted this use accelerated approval, meaning it was approved because many tumors shrank, while studies confirming that it helps people live longer or better are still required. Pemigatinib is also approved for adults with myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement, a rare group of blood and bone marrow cancers, when the disease has come back or not responded to earlier treatment. For this use the rearrangement is identified by chromosome testing of blood or marrow.

How It Works

In these cancers, the broken FGFR gene produces a receptor that is switched on all the time, sending a constant signal that helps the cancer cells grow and survive. Pemigatinib is a kinase inhibitor: it blocks the part of FGFR1, FGFR2 and FGFR3 that passes the signal along. Cutting off that signal can slow the cancer or shrink it. Because the drug acts on the faulty receptor rather than on all dividing cells, it only makes sense for cancers that carry the matching gene change. FGFR signaling also takes place in healthy tissues, so blocking it has predictable effects elsewhere, most notably a rise in blood phosphate.

Dosage & Administration

Pemigatinib is a tablet taken by mouth once a day, with or without food, at about the same time each day. For bile duct cancer it is taken for 14 days in a row followed by 7 days off, repeating in 3-week cycles. For FGFR1-rearranged MLNs it is usually taken every day without a break. Treatment continues as long as it is working and side effects are manageable. Swallow the tablets whole; do not crush, chew, split or dissolve them. If a dose is more than 4 hours late, or if you vomit after taking it, skip it and take the next dose at the usual time rather than taking extra. Dose reductions are common and planned for. The tablets come in three strengths so the care team can lower the dose for side effects, kidney or liver problems, or interacting medicines without stopping treatment.

Side Effects

Raised blood phosphate (hyperphosphatemia) is the most frequent effect, showing up on blood tests in more than 9 in 10 people, often within the first couple of weeks. It usually causes no symptoms at first, but if it stays high, phosphate can combine with calcium and deposit in the skin, blood vessels and other tissues. Regular blood tests check phosphate, and the care team may recommend a low-phosphate diet, a phosphate-lowering medicine, or a dose pause or reduction. Muscle cramps or numbness or tingling around the mouth can signal a sudden change in phosphate and should be reported to the care team right away. Pemigatinib can cause fluid to collect under the retina, the light-sensing layer at the back of the eye (called retinal pigment epithelial detachment). For this reason, eye exams including OCT (optical coherence tomography, a painless scan of the retina) are done before starting, every 2 months for the first 6 months and every 3 months after that. Call the care team promptly about blurred vision, new floaters, flashes of light or any other change in vision. Dry eye is also common and is usually managed with artificial tears or lubricating gels. Other common effects include hair thinning or loss; nail changes such as soreness, discoloration or nails lifting off; mouth sores; dry mouth and dry skin; changes in taste; tiredness; diarrhea or constipation; nausea; reduced appetite; and joint pain. Redness, swelling or pain on the palms and soles can also occur. Most of these are managed with supportive care and dose adjustments.

Interactions & Warnings

Pemigatinib can seriously harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 1 week after the last dose, and men with partners who could become pregnant should do the same. Tell the care team right away about a pregnancy. Do not breastfeed during treatment or for 1 week after the last dose. The liver breaks down pemigatinib using an enzyme called CYP3A. Medicines that strongly or moderately block this enzyme raise drug levels and can make side effects worse, while medicines that speed it up can lower levels enough to make treatment less effective. Many prescription medicines and some herbal supplements affect this enzyme, so the oncologist and pharmacist should review every prescription, over-the-counter product and supplement before anything new is started. Avoid grapefruit and grapefruit juice, which block the same enzyme.

What to Expect

Before starting, the tumor or blood sample must be tested for the FGFR change, and a baseline eye exam and blood tests are done. During treatment, expect regular phosphate checks and scheduled eye exams alongside the usual scans and visits for the cancer itself. In the main study of previously treated FGFR2 bile duct cancer, about a third of people had their tumors shrink substantially, typically within about 3 months, and those responses lasted a median of about 9 months. Others had their cancer stay stable for a time, and some did not benefit. The study had no comparison group, so how much pemigatinib extends life is not yet established. In the small study of FGFR1-rearranged MLNs, most people had the abnormal gene change disappear from chromosome tests, and some were then able to go on to a stem cell transplant. Pemigatinib is meant to control the cancer rather than cure it in most people. Many need a dose pause or reduction at some point, and treatment usually continues until the cancer grows or side effects become too difficult.

Questions to Ask Your Doctor

  1. 1.Has my tumor or blood sample been tested for an FGFR change, and what did the result show?
  2. 2.What benefit might I realistically expect from pemigatinib compared with other options, including clinical trials?
  3. 3.How often will my phosphate be checked, and should I change my diet?
  4. 4.Who will do my eye exams, and who should I call if my vision changes?
  5. 5.Do any of my current medicines or supplements interact with pemigatinib?

Last reviewed • Oct 2026

Educational content, not medical advice.